Andrew Kapoor1, C Sabrina Tan2. 1. Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 2. Division of Infectious Diseases, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue E/CLS 1011, Boston, MA, 02215, USA. ctan@bidmc.harvard.edu.
Abstract
PURPOSE OF REVIEW: The application of immunotherapies to HIV presents a new horizon of treatment options, but little is known about what impact they may have on the central nervous system (CNS). Here we review the most promising immunotherapeutic strategies that can be used to target HIV in the CNS and focus on identifying their potential benefits while exploring the challenges that remain in their application. RECENT FINDINGS: We have identified five immunotherapeutic strategies that hold potential in managing CNS disease among HIV-infected patients. These include broadly neutralizing antibodies, multi-affinity antibodies, CAR-T cell therapy, checkpoint inhibitors, and therapeutic vaccines. Each class of immunotherapy presents unique mechanisms by which CNS viremia and latency may be addressed but are faced with several challenges. CAR-T cell therapy and multi-affinity antibodies seem to hold promise, but combination therapy is likely to be most effective. However, more human trials are needed before the clinical benefits of these therapies are realized.
PURPOSE OF REVIEW: The application of immunotherapies to HIV presents a new horizon of treatment options, but little is known about what impact they may have on the central nervous system (CNS). Here we review the most promising immunotherapeutic strategies that can be used to target HIV in the CNS and focus on identifying their potential benefits while exploring the challenges that remain in their application. RECENT FINDINGS: We have identified five immunotherapeutic strategies that hold potential in managing CNS disease among HIV-infectedpatients. These include broadly neutralizing antibodies, multi-affinity antibodies, CAR-T cell therapy, checkpoint inhibitors, and therapeutic vaccines. Each class of immunotherapy presents unique mechanisms by which CNS viremia and latency may be addressed but are faced with several challenges. CAR-T cell therapy and multi-affinity antibodies seem to hold promise, but combination therapy is likely to be most effective. However, more human trials are needed before the clinical benefits of these therapies are realized.
Authors: John Scholler; Troy L Brady; Gwendolyn Binder-Scholl; Wei-Ting Hwang; Gabriela Plesa; Kristen M Hege; Ashley N Vogel; Michael Kalos; James L Riley; Steven G Deeks; Ronald T Mitsuyasu; Wendy B Bernstein; Naomi E Aronson; Bruce L Levine; Frederic D Bushman; Carl H June Journal: Sci Transl Med Date: 2012-05-02 Impact factor: 17.956
Authors: Lachlan R Gray; Michael Roche; Jacqueline K Flynn; Steve L Wesselingh; Paul R Gorry; Melissa J Churchill Journal: Curr Opin HIV AIDS Date: 2014-11 Impact factor: 4.283
Authors: Chuangqi Wang; Timothy E Schlub; Wen Han Yu; C Sabrina Tan; Karl Stefic; Sara Gianella; Davey M Smith; Douglas A Lauffenburger; Antoine Chaillon; Boris Julg Journal: Clin Infect Dis Date: 2022-10-12 Impact factor: 20.999